FFA
NRIX icon

Farther Finance Advisors’s Nurix Therapeutics NRIX Stock Holding History

Farther Finance Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$95.2K Buy
4,014
+3,545
+756% +$88.4K ﹤0.01% 2898
2026
Q2 		$11.4K Buy
469
+110
+31% +$1.87K ﹤0.01% 4338
2026
Q1 		$5.56K Buy
359
+16
+5% +$265 ﹤0.01% 4436
2025
Q4 		$6.51K Buy
343
+248
+261% +$3.56K ﹤0.01% 4167
2025
Q3 		$878 Buy
95
+86
+956% +$893 ﹤0.01% 4403
2025
Q2 		$103 Buy
+9
New +$97 ﹤0.01% 4312
2025
Q1 		– Sell
-14
Closed -$264 – 4373
2024
Q4 		$264 Hold
14
– – ﹤0.01% 3588
2024
Q3 		$315 Buy
14
+5
+56% +$113 ﹤0.01% 3544
2024
Q2 		$188 Hold
9
– – ﹤0.01% 3506
2024
Q1 		$131 Hold
9
– – ﹤0.01% 3335
2023
Q4 		$93 Buy
+9
New +$62 ﹤0.01% 3310

Other funds holding NRIX

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors's NRIX Position: Q3 2026 in Review

Farther Finance Advisors increased its Nurix Therapeutics (NRIX) stake by 756% in Q3 2026, buying an estimated $88.4K and bringing the position to 4,014 shares worth $95.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2898.

Farther Finance Advisors first reported a position in NRIX in Q4 2023 and has held it in 11 quarters since. 4 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Farther Finance Advisors held 4,014 shares of Nurix Therapeutics worth $95.2K as of Q3 2026.
  • Farther Finance Advisors bought 3,545 Nurix Therapeutics shares in Q3 2026, an estimated $88.4K.
  • Nurix Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #2898 holding.
  • Farther Finance Advisors first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 4 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.